SEC Form 4 · accession 0001229765-26-000008
Adaptive Biotechnologies Corp · ADPT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michelle Renee Griffin
Director
Period of report
Jun 25, 2026
Accepted (ET)
Jun 29, 2026 · 7:49 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001478320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 25, 2026 | M | 52,084 | $7.80 | A | 67,709 | D | |
| Common StockF2 | Jun 25, 2026 | S | 52,084 | $20.18 | D | 15,625 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F3 | $7.80 | Jun 25, 2026 | M | 52,084 | D | — | Apr 23, 2029 | Common Stock | 52,084 | 0 | D |
Explanation of responses
- F1The transactions reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 7, 2025.
- F2The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $20.00 to $20.55, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- F3The option was fully vested and exercisable.